4.6 Article

The Impact of Disulfiram Treatment on the Reinforcing Effects of Cocaine: A Randomized Clinical Trial

Journal

PLOS ONE
Volume 7, Issue 11, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0047702

Keywords

-

Funding

  1. National Institutes of Health [R01 DA017705, K24 DA017754, M01 RR00188]

Ask authors/readers for more resources

Background: Clinical trials indicate that disulfiram (250 mg/d) reduces cocaine use, though one study found that treatment with lower doses of disulfiram (62.5 and 125 mg/d) increased cocaine use. We conducted the present study to better understand how disulfiram alters the reinforcing effects of cocaine in cocaine users. Methods: Seventeen non-treatment seeking, cocaine-dependent volunteers participated in this double-blind, placebo-controlled, laboratory-based study. A cross-over design was utilized in which participants received placebo in one phase and disulfiram (250 mg/d) in the other. Following three days of study medication participants completed two choice sessions. In one they made 10 choices between receiving an intravenous infusion of saline or money that increased in value (US$ 0.05-16) and in the other cocaine (20 mg) or money. Results: Participants chose cocaine more than saline under both disulfiram and placebo conditions (p<0.05). Unexpectedly, disulfiram increased both the number of cocaine and saline infusion choices (p<0.05). We next examined the relationship between disulfiram dose and cocaine choices. Disulfiram dose (mg/kg bodyweight) was negatively correlated with number of choices for cocaine (p<0.05). Disulfiram also enhanced cocaine-induced increases in cardiovascular measures (p's<0.05-0.01). Conclusions: Disulfiram's impact on the reinforcing effects of cocaine depends on dose relative to body weight. Our results suggest that the use of weight-based medication doses would produce more reliable effects, consistent with weight-based dosing used in pediatrics and in preclinical research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychology, Biological

Assessment of Demand for Methamphetamine and Cigarettes Among Individuals With Methamphetamine Use Disorder

Jin H. Yoon, Robert Suchting, Rachel N. Cassidy, Peter K. Bolin, Yasmine Omar, Gregory S. Brown, Richard De la Garza

Summary: The study aimed to assess demand for MA using a hypothetical drug purchasing task and found multiple positive relationships between self-reported drug use and demand for each drug. Comparing MA to cigarettes, it revealed greater abuse liability for MA compared to cigarettes.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY (2021)

Article Oncology

Clinical relevance of a Body Image Scale cut point of 10 as an indicator of psychological distress in cancer patients: results from a psychiatric oncology clinic

Deepti Chopra, Richard De La Garza, Tamara E. Lacourt

Summary: This study evaluated the previously suggested BIS cut point score of >= 10 as an indicator of psychological distress, finding a positive association with depression, anxiety, and distress scores. A BIS score >= 10 was a significant predictor of moderate depression and anxiety, suggesting the importance of follow-up and appropriate referral for patients with higher scores.

SUPPORTIVE CARE IN CANCER (2021)

Article Neurosciences

Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress

Jack E. Henningfield, Sherecce Fields, James C. Anthony, Lawrence S. Brown, Carlos A. Bolanos-Guzman, Sandra D. Comer, Richard De La Garza, Debra Furr-Holden, Albert Garcia-Romeu, Dorothy K. Hatsukami, Armin Raznahan, Carlos A. Zarate

Summary: Higher levels of excellence and innovation in research can be achieved by promoting equity, diversity, and inclusion in organizations. ACNP has made progress in increasing diversity, especially in female membership and leadership positions, but there is still room for improvement in areas like African American and other ethnic populations. Collaboration with other organizations committed to these goals may help accelerate progress towards fostering diversity and inclusion in scientific organizations.

NEUROPSYCHOPHARMACOLOGY (2021)

Article Psychiatry

Mental Health Practitioners' Immediate Practical Response During the COVID-19 Pandemic: Observational Questionnaire Study

Shannon E. Reilly, Katherine L. Zane, William T. McCuddy, Zachary A. Soulliard, David M. Scarisbrick, Liv E. Miller, James J. Mahoney

JMIR MENTAL HEALTH (2020)

Article Psychology, Clinical

Neuropsychologists' practice adjustments: the impact of COVID-19

Katherine L. Zane, Nicholas S. Thaler, Shannon E. Reilly, James J. Mahoney, David M. Scarisbrick

Summary: The field of neuropsychology rapidly adapted during the COVID-19 pandemic, with an increased focus on tele-neuropsychology services. Most neuropsychologists reported experiencing distress and anxiety related to the pandemic, yet this did not significantly impact their overall ability to practice. Further research is necessary to evaluate the long-term viability and sustainability of tele-neuropsychology practice.

CLINICAL NEUROPSYCHOLOGIST (2021)

Article Psychology, Clinical

High prevalence of co-occurring substance use in individuals with opioid use disorder

James J. Mahoney, Erin L. Winstanley, Laura R. Lander, James H. Berry, Patrick J. Marshalek, Marc W. Haut, Jennifer L. Marton, Wesley D. Kimble, Matthew Armistead, Sijin Wen, Yilin Cai, Sally L. Hodder

Summary: This study in West Virginia found that the prevalence of co-occurring substance use among patients with opioid use disorder (OUD) is high at 72.8%, with benzodiazepines being the most common co-occurring substance. Patients who used co-occurring substances were younger and had a higher prevalence of hepatitis C virus (HCV) compared to those who used opioids alone, with minimal gender differences.

ADDICTIVE BEHAVIORS (2021)

Letter Neurosciences

Reply to Drs. Hart and Cadet: we agree-the challenges of increasing equity, diversity and inclusion include societal issues and actions now are vital

Jack E. Henningfield, Sherecce Fields, James C. Anthony, Lawrence S. Brown, Carlos A. Bolanos-Guzman, Sandra D. Comer, Richard De La Garza, Debra Furr-Holden, Albert Garcia-Romeu, Dorothy Hatsukami, Armin Raznahan, Carlos A. Zarate

NEUROPSYCHOPHARMACOLOGY (2021)

Review Substance Abuse

Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review

Erin L. Winstanley, James J. Mahoney, Felipe Castillo, Sandra D. Comer

Summary: This review analyzed 70 studies on neurocognitive impairments and brain abnormalities associated with opioid-related overdoses, finding methodological limitations in existing research, but overall supporting the link between opioid overdoses and brain injuries and cognitive impairments.

DRUG AND ALCOHOL DEPENDENCE (2021)

Article Oncology

Frequency of anxiety and depression and screening performance of the Edmonton Symptom Assessment Scale in a psycho-oncology clinic

Alan Valentine, Jessica Brown, Tamara Lacourt, Minxing Chen, Richard De La Garza, Eduardo Bruera

Summary: The study found that self-reported depression and anxiety are common symptoms among patients at a psychiatric oncology center for an initial visit. ESAS-A and ESAS-D have good sensitivity for anxiety and depression screening of cancer patients.

PSYCHO-ONCOLOGY (2022)

Article Clinical Neurology

Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents

Claire K. Morice, Luba Yammine, Jin Yoon, Scott D. Lane, Joy M. Schmitz, Thomas R. Kosten, Richard De la Garza, Christopher D. Verrico

Summary: Individuals with both PTSD and AUD have more severe symptoms and poorer treatment outcomes compared to those with PTSD or AUD alone. However, there is a lack of evidence and FDA-approved treatments for comorbid PTSD and AUD. This manuscript reviews a potential target for treating comorbid AUD in persons with PTSD.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2022)

Article Biochemistry & Molecular Biology

Cortical thickness and related depressive symptoms in early abstinence from chronic methamphetamine use

Johannes Petzold, Andy C. Dean, Jean-Baptiste Pochon, Dara G. Ghahremani, Richard De la Garza, Edythe D. London

Summary: Methamphetamine use disorder is associated with thinner cortex in regions related to craving and depressive symptoms. Identifying this brain structure abnormality may help identify patients with Methamphetamine Use Disorder who will benefit from antidepressant medication.

ADDICTION BIOLOGY (2022)

Article Substance Abuse

Promoter region variant C-824T in the TH gene modulates the subjective effects of cocaine

Peter K. Bolin, Ellen M. Nielsen, David A. Nielsen, Richard De la Garza

Summary: This study investigated the impact of a promoter variant of the TH gene (rs10770141) on the subjective effects of cocaine in 65 nontreatment-seeking individuals with cocaine dependence. Participants received intravenous cocaine/saline, and the TH genotypes were evaluated. Homozygous individuals for the minor T allele reported stronger positive and negative subjective effects to cocaine compared to those with the major C allele. The findings suggest that TH rs10770141 modulates the subjective effects of cocaine in individuals with cocaine dependence.

AMERICAN JOURNAL ON ADDICTIONS (2023)

Letter Neurosciences

Low-Intensity Focused Ultrasound Targeting the Bilateral Nucleus Accumbens as a Potential Treatment for Substance Use Disorder: A First-in- Human Report

James J. Mahoney III, Daisy G. Y. Thompson-Lake, Manish Ranjan, Jennifer L. Marton, Jeffrey S. Carpenter, Wanhong Zheng, James H. Berry, Daniel L. Farmer, Pierre D'Haese, Victor S. Finomore, Padma Tirumalai, Ashley S. Mears, Jacob Suffridge, Ashley Ames, Sally L. Hodder, Ali R. Rezai

BIOLOGICAL PSYCHIATRY (2023)

Article Psychology, Biological

Deep Brain Stimulation of the Nucleus Accumbens/Ventral Capsule for Severe and Intractable Opioid and Benzodiazepine Use Disorder

James J. Mahoney, Marc W. Haut, Sally L. Hodder, Wanhong Zheng, Laura R. Lander, James H. Berry, Daniel L. Farmer, Jennifer L. Marton, Manish Ranjan, Nicholas J. Brandmeir, Victor S. Finomore, Jeremy L. Hensley, Will M. Aklin, Gene-Jack Wang, Dardo Tomasi, Ehsan Shokri-Kojori, Ali R. Rezai

Summary: This study evaluated the safety of DBS for substance use disorder and its effects on substance use, craving, emotional symptoms, and frontal/executive functions. The results showed that DBS of the NAc/VC was safe and effective in reducing substance use and craving, as well as improving frontal and executive functions. Confirmation of these findings with future studies is needed.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY (2021)

Article Psychology, Multidisciplinary

Frequency and perceived effectiveness of mental health providers' coping strategies during COVID-19

Shannon E. Reilly, Zachary A. Soulliard, William T. McCuddy, James J. Mahoney

Summary: The study surveyed 888 mental health practitioners on the coping strategies they used during the COVID-19 pandemic. The majority of respondents utilized behavioral coping strategies, such as distraction, spending time with loved ones, and exercise. While some used alcohol to cope, trainees were more likely to use supervision and substances other than alcohol or tobacco to manage anxiety/distress.

CURRENT PSYCHOLOGY (2021)

No Data Available